Baricitinib As Potential Treatment for 2019-Ncov Acute Respiratory Disease

Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced. Results of rapid sequencing of 2019-nCoV, coupled with molecular modelling based on the genomes of related virus proteins,1Gruber CC Steinkellner G Wuhan coronavirus 2019-nCoV—what we can find out on a structural bioinformatics level.https://innophore.com/2019-ncov/Date: Jan 23, 2020Date accessed: February 3, 2020Google Scholar have suggested a few compounds that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination. BenevolentAI's knowledge graph is a large repository of structured medical information, including numerous connections extracted from scientific literature by machine learning.2Segler MHS Preuss M Waller P Planning chemical syntheses with deep neural networks and symbolic AI.Nature. 2018; 555: 604-610Crossref PubMed Scopus (1078) Google Scholar Together with customisations bespoke to 2019-nCoV, we used BenevolentAI to search for approved drugs that could help, focusing on those that might block the viral infection process. We identified baricitinib, which is predicted to reduce the ability of the virus to infect lung cells. Most viruses enter cells through receptor-mediated endocytosis. The receptor that 2019-nCoV uses to infect lung cells might be ACE2, a cell-surface protein on cells in the kidney, blood vessels, heart, and, importantly, lung AT2 alveolar epithelial cells (figure). These AT2 cells are particularly prone to viral infection.3Zhao Y Zhao Z Wang Y et al.Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov.BioRxiv. 2020; (published online Jan 26.)DOI:https://doi.19985Google Scholar One of the known regulators of endocytosis is the AP2-associated protein kinase 1 (AAK1). Disruption of AAK1 might, in turn, interrupt the passage of the virus into cells and also the intracellular assembly of virus particles.4Lu R Zhao X Li J et al.Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.Lancet. 2020; (published online Jan 30.)https://doi.org/10.1016/S0140-6736(20)30251-8Summary Full Text Full Text PDF Scopus (8212) Google Scholar Of 378 AAK1 inhibitors in the knowledge graph, 47 have been approved for medical use and six inhibited AAK1 with high affinity. These included a number of oncology drugs such as sunitinib and erlotinib, both of which have been shown to inhibit viral infection of cells through the inhibition of AAK1.5Pu SY Xiao F Schor S et al.Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.Antiviral Res. 2018; 155: 67-75Crossref PubMed Scopus (77) Google Scholar However, these compounds bring serious side-effects, and our data infer high doses to inhibit AAK1 effectively. We do not consider these drugs would be a safe therapy for a population of sick and infected people. By contrast, one of the six high-affinity AAK1-binding drugs was the janus kinase inhibitor baricitinib, which also binds the cyclin G-associated kinase, another regulator of endocytosis. Because the plasma concentration of baricitinib on therapeutic dosing (either as 2 mg or 4 mg once daily) is sufficient to inhibit AAK1, we suggest it could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and the inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.7Chen N Zhou M Dong X et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet. 2020; (published online Jan 29.)https://doi.org/10.1016/S0140-6736(20)30211-7Summary Full Text Full Text PDF Scopus (14363) Google Scholar This online publication has been corrected. The corrected version first appeared at thelancet.com on June 18, 2020 This online publication has been corrected. The corrected version first appeared at thelancet.com on June 18, 2020 JS is editor-in-chief of Oncogene. JS has previously sat on a number of scientific advisory boards, including BenevolentAI, and has consulted with Lansdowne partners, Vitruvian, and Social Impact Capital; he now sits on the Board of Directors for BB Biotech Healthcare Trust and chairs Xerion Healthcare. All other authors are employees of BenevolentAI. Events in relation to the 2019-nCoV outbreak are evolving rapidly, and we make our initial thoughts available in this Correspondence in good faith and to assist in the global response. Our early investigations and suggestions require further detailed work and analysis and should not be relied on as constituting any kind of medical or other advice or recommendation. Department of ErrorRichardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395: e30–31—In this Correspondence, the authors Michael Rawling and Edward Savory (BenevolentAI, London, UK) were mistakenly omitted. This correction has been made to the online version as of June 18, 2020. Full-Text PDF